Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
- Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY-Combo-I
- Sponsors Sanofi
- 17 Oct 2021 Results of Meta-Analysis from eight randomized, double-blind, placebo-controlled studies assessing Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD published in the Pharmacotherapy
- 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
- 01 Jun 2018 Results of a pooled analysis of 5 studies (LONG TERM, HIGH FH, FH I, FH II and COMBO) assessing the safety and efficacy of Alirocumab, published in the Diabetes Therapy